Bases for the study of the safety of medicines. The spectrum of rare and unexpected ad-verse reactions of bisphosphonates
I S Dydykina, P S Dydykina, Yu V Muravyev
Современная ревматология · 2011
doi:10.14412/1996-7012-2011-706 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The paper presents a classification of adverse drug reactions and their characteristics. Bisphophonates (BP) that are have been prescribed for more than 30 years to prevent and treat all forms of osteoporosis (OP) and recognized as first-line drugs for its treatment are used as an example to see the history of investigating rare and unexpected adverse reactions. The direct correlation between the rare adverse reactions of Ps and their use remains to be proven today. The proposal to reduce the prescriptions of BPs is unfounded. The evidence for the efficacy and safety of BPs in OP has been obtained and confirmed by multiple trials and many years X real practice. Alendronate (fosavance) is the most studied BP now.
Abstract licence: CC BY
References59
59 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.